ImmunArray (IAL) is developing in-vitro diagnostic tests based on its iCHIP microarray technology platform. The products support a personalized medicine approach, and IAL's first product family will provide tests for diagnosis, prognosis, and therapeutic guidance for autoimmune diseases and improving transplantation medicine.

ImmunArray's iCHIP technology mines the information stored in immune system repertoires in order to shed light on an individual's specific immune profile. The iCHIP platform measures an individual's auto-antibody repertoires in a drop of blood using microarray technology. Global patterns of antibodies are detected via proprietary sets of antigens and analyzed to provide a highly specific diagnostic and prognostic profile of the individual.

The company is also developing a set of markers of traumatic brain injury, both as standalone acute care tests and as iCHIP components to monitor for the emergence of chronic sequelae of traumatic brain injury.

ImmunArray holds an exclusive, worldwide license from the Weizmann Institute of Science for the iCHIP technology. The company also has licenses from Brigham and Women's Hospital and Johns Hopkins University for additional components of the technology.